Asia Pacific Automated Cell Counters Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type and End User

The automated cell counters market in Asia Pacific is expected to grow from US$ 1,556.29 million in 2022 to US$ 2,263.92 million by 2028. It is estimated to grow at a CAGR of 6.4% from 2022 to 2028.

Chronic diseases are conditions that are present in an individual for one or more years and require ongoing medical attention. Chronic diseases are currently the major cause of death among adults in several countries of APAC. Infectious diseases are caused by infectious agents, including viruses, bacteria, parasites, fungi, and toxic products. HIV is a major public health issue across APAC. As per The Joint United Nations Programme on HIV/AIDS (UNAIDS), ~37.7 million people had HIV in 2020; out of these, 1.7 million were children aged 0-14 years, and 36 million were adults. Similarly, hepatitis is inflammation of the liver caused by a viral infection. The five primary strains of hepatitis viruses are A, B, C, D, and E. According to WHO, ~58 million people had chronic hepatitis C in 2019, and ~1.5 million new infections occur every year. As per WHO, tuberculosis (TB) is the thirteenth leading cause of death globally and the second leading infectious disease after COVID-19. Furthermore, thirty countries with high TB burdens accounted for 86% of new TB cases in 2020. Eight countries registered two-thirds of the total TB cases, with India at the forefront, followed by China, the Philippines, Indonesia, Nigeria, Pakistan, and Bangladesh. Diagnostics are essential in determining the direction of any medical treatment of infectious and chronic diseases. Cell counting is one of the methods that is used for the detection of such diseases. Therefore, the rising prevalence of infectious and chronic diseases across the APAC is driving the growth of the automated cell counters market.

Market Overview

The Asia Pacific automated cell counters market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth is attributed to the rising geriatric population and increasing research activities in stem cells, genomics, and proteomics. For instance, in 2018, Sysmex Corporation launched XS-500ix, an automated Hematology Analyzer, in the Chinese market. Therefore, the Chinese government has promoted policies for allocating medical resources to increase efficiency. As a result, the demand for sophisticated and high-quality products in China is likely to increase, which is expected to boost the market growth. Thus, increasing disease cases and technological development in China drive the automated cell counters market over the forecast period

Asia Pacific Automated cell counters Market Segmentation

The Asia Pacific automated cell counters market is segmented on the basis of type, end user, and country. Based on type, the market is segmented into hemocytometer, flow cytometers, electrical impedance coulter counters, and spectrophotometers. The spectrophotometers segment held the largest market share in 2022. Based on end user, the market is categorized into hospitals, research laboratories, diagnostics centers, and others. The hospitals segment held the largest market share in 2022. Based on country, the market is segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market share in 2022.

Eppendorf; Thermo Fisher Scientific Inc.; Countstar Inc.; Bio-Rad Laboratories, Inc.; F. Hoffman-La Roche Ltd; Chemometec A/S; ALIGNED GENETICS; Beckman Coulter, Inc. (Danaher); Nanoentek; Olympus Corporation; MERCK KGaA; Sysmex Corporation; Agilent Technologies, Inc.; Abbott; and Nexcelom Bioscience LLC. are the leading companies operating in the Asia Pacific automated cell counters market.